The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The future of CLL treatment and more personalized approaches
Paula Cramer, MD, University of Cologne, Cologne, Germany, briefly discusses the importance of personalized treatment approaches in patients with chronic lymphocytic leukemia (CLL). Dr Cramer first highlights that several factors must be considered when making decisions about treatment personalization, and then goes on to share her thoughts on where the field is moving. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
